Back to Journals » OncoTargets and Therapy » Volume 11

Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report

Authors Xie S, Wu Z, Zhou L, Liang Y, Wang X, Niu L, Xu K, Chen J, Zhang M

Received 28 February 2018

Accepted for publication 10 August 2018

Published 25 October 2018 Volume 2018:11 Pages 7345—7352

DOI https://doi.org/10.2147/OTT.S166962

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 4

Editor who approved publication: Dr Arseniy Yuzhalin


Silun Xie,1 Zhengyi Wu,1 Liang Zhou,2 Yingqing Liang,2 Xiaohua Wang,2 Lizhi Niu,2 Kecheng Xu,2 Jibing Chen,2 Mingjie Zhang1

1Research and Development Department, Shenzhen Hank Bioengineering Institute, Shenzhen 518004, China; 2Department of Central Laboratory, Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China

Abstract: For advanced hepatocellular carcinoma (HCC) patients, liver transplantation (LT) is an optimal treatment with limitation of high risk of tumor recurrence related to the immunosuppressive chemotherapy as usually recommended. In this study, a 29-year-old man suffered from HCC recurrence after LT. He underwent radiotherapy (total dose: 45 Gy) but had no significant response. Then, he received iodine-125 seed implantation combined with allogenic natural killer (NK) cell immunotherapy. Liver function, immune function, circulating tumor cell counts and computed tomography scans were evaluated to determine the clinical effect. We found that this combined treatment produced enhanced immune function of the patient and reduction in tumor size. This is the first report of an efficacy and safety study about clinical regimen comprising allogenic NK cell immunotherapy combined with iodine-125 seed implantation for the treatment of HCC recurrence after LT.

Keywords: hepatic carcinoma, iodine seeds implantation, natural killer cells, allogenic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]